Chalcogen Or Nitrogen Bonded Directly At 1-, 3-, Or 5-position By Nonionic Bonding Patents (Class 514/390)
-
Patent number: 8450337Abstract: Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.Type: GrantFiled: September 30, 2009Date of Patent: May 28, 2013Assignee: Moleculin, LLCInventors: Waldemar Priebe, Charles Conrad, Timothy Madden
-
Publication number: 20130123215Abstract: The present invention relates to novel 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.Type: ApplicationFiled: November 9, 2012Publication date: May 16, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Patent number: 8431607Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).Type: GrantFiled: December 12, 2007Date of Patent: April 30, 2013Assignee: IRM LLC, A Delaware Limited Liability CompanyInventors: Hong Liu, Xiaohui He, Dean Phillips, Xuefeng Zhu, Kunyong Yang, Thomas Lau, Baogen Wu, Yongping Xie, Truc Ngoc Nguyen, Xing Wang
-
Publication number: 20130096111Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.Type: ApplicationFiled: September 17, 2012Publication date: April 18, 2013Applicant: The Board of Regents of The University of Texas SystemInventor: The Board of Regents of The University of Texas S
-
Publication number: 20130039995Abstract: Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: wherein R is a hydrogen atom, a hydroxyl radical, a branched or unbranched alkyl radical having from 1 to 4 carbon atoms, an alkoxy radical having from 1 to 10 carbon atoms or a cycloaliphatic radical which is substituted or unsubstituted, and at least one anti-irritant compound and benzoyl peroxide.Type: ApplicationFiled: October 12, 2012Publication date: February 14, 2013Applicant: Galderma Research & DevelopmentInventor: Galderma Research & Development
-
Patent number: 8372825Abstract: Skin compositions comprising, hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and related method for protecting, healing and/or soothing the skin comprising: applying an effective amount of a cosmetic preparation selected from the group consisting of hand cream, foot cream, body cream, lip cream, lip gloss, lip stick, gel, balm and lotion to the skin surface; wherein said cosmetic preparation includes a skin composition made of hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and said effective amount is enough to protect, heal and/or soothe the skin surface.Type: GrantFiled: August 13, 2009Date of Patent: February 12, 2013Inventor: Norman Turkowitz
-
Publication number: 20130030030Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.Type: ApplicationFiled: October 4, 2012Publication date: January 31, 2013Applicant: ALWYN COMPANY, INC.Inventor: Alwyn Company, Inc.
-
Publication number: 20130023529Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.Type: ApplicationFiled: July 11, 2012Publication date: January 24, 2013Applicant: The Board of Regents of the University of Texas SystemInventors: Satish K. Srivastava, Kota V. Ramana
-
Publication number: 20120329760Abstract: Methods of identifying a subject having a urinary tract infection using RNase 7 are described. The methods include providing a test sample of urine from the subject, determining the level of RNase 7 in the test sample, and then comparing the level of RNase 7 in the test sample to the level of RNase 7 in a control. A higher level of RNase 7 in the test sample indicates that the subject has an acute urinary tract infection, whereas a lower level of RNase 7 in the test sample indicates that the subject only has a chronic urinary tract infection.Type: ApplicationFiled: April 19, 2012Publication date: December 27, 2012Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.Inventors: David Hains, Andrew Lawrence Schwaderer, John David Spenser
-
Publication number: 20120308671Abstract: Nose ointment for the prophylaxis of inhalation allergic reactions comprising at least one mixture of saturated hydrocarbons characterized in that the at least one mixture of saturated hydrocarbons has a viscosity by the DIN 51 562 method of >6 mm2/s (100° C.).Type: ApplicationFiled: May 14, 2012Publication date: December 6, 2012Applicant: PHYT-IMMUN GmbHInventor: Peter Theiss
-
Patent number: 8324244Abstract: The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.Type: GrantFiled: September 28, 2010Date of Patent: December 4, 2012Assignee: Gilead Sciences, Inc.Inventors: Eric Dowdy, Xi Chen, Steven Pfeiffer
-
Publication number: 20120283302Abstract: A SCCA-1 production inhibitor, comprising as an active ingredient, at least one carboxamide derivative selected from the group consisting of compounds represented by the following formula (I): wherein X is CR5 or N, R1, R4 and R5 each independently represent hydrogen, C1-C4 alkyl or a C1-C6 hydroxyalkyl group having 1-5 hydroxy groups, R2 and R3 each independently represent hydrogen, C1-C4 alkyl or a C1-C6 hydroxyalkyl group having 1-5 hydroxy groups, or each represents a group —(CH2)n—, wherein n represents an integer of 1 or 2, and may form a 5- to 6-membered ring together with the atoms to which they are bonded and with the carbonyl group, allantoin, and salts thereof.Type: ApplicationFiled: April 28, 2010Publication date: November 8, 2012Applicant: SHISEIDO COMPANY, LTDInventors: Maki Kaneko, Takuya Hiruma, Masaru Suetsugu, Chika Katagiri, Toshii Iida, Tomoko Onodera
-
Patent number: 8283370Abstract: Embodiments disclosed herein relate to new imidazolidinedione derivatives, methods of making these compounds, and methods of using the same to prevent, treat, or inhibit malaria in a subject.Type: GrantFiled: October 2, 2009Date of Patent: October 9, 2012Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Ai Jeng Lin, Michael P. Kozar, Michael T. O'Neil, Alan J. Magill, David L. Saunders
-
Patent number: 8236963Abstract: The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the modulation of CRTH2 activity.Type: GrantFiled: May 23, 2006Date of Patent: August 7, 2012Assignee: Merck Serono SAInventors: Matthias Schwarz, Eric Sebille, Christophe Cleva, Cedric Merlot, Dennis Church, Patrick Page, Jacqueline A. Macritchie, John Frederick Atherall, Stefano Crosignani, Doris Pupowicz
-
Publication number: 20120189684Abstract: This invention relates to skincare compositions, in particular compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin that involve the application of such compositions, wherein the compositions comprise salicylic acid or a salt thereof in combination with at 2 actives selected from the group consisting of lactic acid or a salt thereof; glycyrrhizinic acid or a salt or derivative thereof; bisabolol; cetylhydroxyproline palmitamide; allantoin; niacinamide; and epilobium angustifolium extract.Type: ApplicationFiled: July 19, 2010Publication date: July 26, 2012Applicant: Reckitt Benckiser Healthcare International LimitedInventors: Carolyn Buckley, Stuart Jackson, Neil Kilcullen, Diane Marie Pavis
-
Publication number: 20120165379Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.Type: ApplicationFiled: February 29, 2012Publication date: June 28, 2012Applicant: ALWYN COMPANY INC.Inventor: Elliott FARBER
-
Publication number: 20120148508Abstract: The invention relates to a coloured fragrancing composition comprising, in a cosmetically acceptable medium: a) at least 2% by weight of a fragrancing substance relative to the total weight of the composition; b) at least one derivative of: benzylidene camphor containing a sulphonic function or a benzotriazole silicone of particular formula (1) that will be defined below in detail; c) at least one dye that is soluble in said medium; said composition not containing an alkyl ?,??-diphenylacrylate compound or an alkyl ?-cyano-?,??-diphenylacrylate compound. The invention also relates to a cosmetic method for fragrancing human keratin substances and in particular the skin, lips and integuments, comprising the application to the keratin substances of the composition defined previously.Type: ApplicationFiled: November 18, 2010Publication date: June 14, 2012Applicant: L'OREALInventors: Willy Thfoin, Boris Grimal
-
Publication number: 20120148520Abstract: The present inventions relate to a number of fields including wound healing, a waterless antibacterial disinfectant, a surgical scrub, insect repellant, and methods of treating traumatic injuries, particularly those on the battlefield where there is a need to stabilize the patient and prevent infection.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Inventors: Michael Strobel, Gene Komer
-
Patent number: 8193228Abstract: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.Type: GrantFiled: October 16, 2007Date of Patent: June 5, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: David Chen, Christopher L. Franklin, Peter R. Guzzo, Linus S. Lin, Michael M. C. Lo, Ravi P. Nargund, Iyassu K. Sebhat
-
Publication number: 20120134929Abstract: The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.Type: ApplicationFiled: July 23, 2010Publication date: May 31, 2012Inventors: Michael S. McGrath, Arasteh Ari Azhir
-
Publication number: 20120128654Abstract: Methods for inhibiting the progression of neurodegenerative diseases and treating neurotrauma-induced damage and cerebrovascular disease are provided herein, the methods including the administration of a safe and effective amount of allantoin to a patient in need thereof. Also provided are pharmaceutical compositions including allantoin for the inhibition of the progression of neurodegenerative diseases and for the treatment of neurotrauma-induced damage and cerebrovascular disease.Type: ApplicationFiled: April 23, 2010Publication date: May 24, 2012Applicant: UNIVERSITY OF CINCINNATIInventors: Brian T. Terpstra, Caryl E. Sortwell
-
Patent number: 8183275Abstract: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.Type: GrantFiled: October 16, 2007Date of Patent: May 22, 2012Assignees: Merck Sharp & Dohme Corp., Albany Molecular Research, Inc.Inventors: Peter H. Dobbelaar, Christopher L. Franklin, Allan Goodman, Cheng Guo, Peter R. Guzzo, Mark Hadden, Shuwen He, Alan J. Henderson, Tianying Jian, Linus S. Lin, Jian Liu, Ravi P. Nargund, Megan Ruenz, Bruce J. Sargent, Iyassu K. Sebhat, Larry Yet
-
Publication number: 20120121662Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.Type: ApplicationFiled: January 19, 2012Publication date: May 17, 2012Applicant: LYOTROPIC THERAPEUTICS, INC.Inventors: David Anderson, Benjamin G. Cameransi, JR., Vincent M. Conklin
-
Publication number: 20120121663Abstract: Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.Type: ApplicationFiled: January 19, 2012Publication date: May 17, 2012Applicant: LYOTROPIC THERAPEUTICS, INC.Inventors: David Anderson, Benjamin G. Cameransi, JR., Vincent M. Conklin
-
Publication number: 20120065238Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.Type: ApplicationFiled: November 14, 2011Publication date: March 15, 2012Applicant: ALWYN COMPANY, INC.Inventor: Elliott Farber
-
Publication number: 20120040970Abstract: The present invention provides a method for rapidly and reliably delivering dantrolene, or derivatives thereof, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment or prevention of malignant hyperthermia (MH), spasticity, and Ecstasy intoxication. The present invention further provides intranasal pharmaceutical compositions comprising dantrolene sodium or any pharmaceutically acceptable salts thereof in a variety of pharmaceutical dosage forms, with and without other compounds.Type: ApplicationFiled: April 26, 2010Publication date: February 16, 2012Inventor: Abeer M. Al-Ghananeem
-
Patent number: 8106080Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: GrantFiled: June 8, 2006Date of Patent: January 31, 2012Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Publication number: 20120009253Abstract: Use of an anti-inflammatory agent such as povidone iodine for the preparation of a pharmaceutical composition for the treatment of diseases of the lower respiratory tract which are susceptible to the administration of such agents.Type: ApplicationFiled: September 22, 2011Publication date: January 12, 2012Inventors: Wolfgang Fleischer, Karen Reimer
-
Publication number: 20110311658Abstract: A topical composition comprising at least one active agent selected from a depilatory agent (s), an agent (s) for preventing or reducing the growth or re-growth of hair and an agent (s) for preventing or reducing in-growing hair, and a gas, wherein the at least one active agent and gas are dispersed in a cosmetically acceptable medium.Type: ApplicationFiled: January 15, 2010Publication date: December 22, 2011Applicant: Reckitt & Colman (Overseas) LimitedInventors: Magali Bertrand, Philippe Henriat
-
Publication number: 20110262550Abstract: A method for treating a skin ailment by applying a personal composition from a collapsible dispenser. The collapsible dispenser includes a collapsible bag at least partially surrounded by an elastically deformable member and, optionally, an outer container body. Potential energy is generated by stretching the elastically deformable member, which is used to dispense the composition in lieu of a propellant or pump. The personal care composition may be a skin care composition, an antifungal, or an enzyme inhibiting composition.Type: ApplicationFiled: April 26, 2010Publication date: October 27, 2011Inventors: Thomas James Klofta, Gary Dean Lavon, Thomas Edward Schulte
-
Publication number: 20110262558Abstract: An improved composition for skin cleansing and protection is disclosed. The composition contains an effective amount of at least one alpha-hydroxyl acid or a pharmaceutically acceptable salt thereof, at least one base, one surfactant and one skin protectant. Various additives and excipients may be included in the formulation. The improved composition disclosed herein achieves a higher bacteria killing rate and shows longer action duration. The disclosed composition is capable of penetrating deep into the skin which allows for delivery of more anti-microbials to sites that are at a higher risk of being infected. Various modifications of the improved composition are also disclosed.Type: ApplicationFiled: April 27, 2011Publication date: October 27, 2011Inventors: Roger Huckfeldt, Phillip Finley
-
Publication number: 20110263486Abstract: The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein Y is —NRaRb, —NRc?ONRaRb, —NRcC?SNRaRb, —NRcC?NRdNaRb, heterocycle, —C?ONRaRb, heterocycle, or aryl; n is 0 to 8; m is 0, or 1; r is 0 to 3; t is 0 to 3; X is O or N; Z is CH2, C?O, C?S or a single bond; Z1 is CO—R2, CS—R2, (CH2)t—R2 or the side-chain of a naturally occurring amino acid; Z2 is CO—R2, CS—R2 or (CH2)t—R3 or the side-chain of a naturally occurring amino acid; Z3 is CO—R2, CS—R2 or (CH2)t—R4 or the side-chain of a naturally occurring amino acid; Z4 is H, alkyl, alkoxy, or cycloalkyl; R1, R2, R3, and R4 are independently from each other H, OH, SH, NH2, CN, NO2, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkylthio, haloalkyloxy, hydroxyalkyl, hydroxyalkylamino, alkylamino, alkylaryl, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxyalkyl, alkoxy, aryloxy, heteroaryl, aryl, or halogen.Type: ApplicationFiled: March 11, 2011Publication date: October 27, 2011Applicant: 4SC AGInventors: Johann LEBAN, Martin KRALIK
-
Publication number: 20110230533Abstract: Embodiments disclosed herein relate to new imidazolidinedione derivatives, methods of making these compounds, and methods of using the same to prevent, treat, or inhibit malaria in a subject.Type: ApplicationFiled: October 2, 2009Publication date: September 22, 2011Inventors: Ai Jeng Lin, Michael P. Kozar, Michael T. O'Neil, Alan J. Magill, David L. Saunders
-
Publication number: 20110224599Abstract: There is provided wound healing composition which comprises at least one oxidant, at least one photoactivator capable of actuating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.Type: ApplicationFiled: November 6, 2009Publication date: September 15, 2011Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
-
Publication number: 20110218482Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 6, 2009Publication date: September 8, 2011Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
-
Publication number: 20110195137Abstract: The invention relates to a method of treating the coat of an animal. The method includes the steps of applying a composition to the coat of the animal, diffusing the composition by action of a carrier, storing the active ingredients of the composition by the sebaceous glands of the animal, and gradually releasing the active ingredients from the sebaceous glands. The dermo-cosmetic composition includes a diffusion solvent vehicle that enables, by a simple application to one or more points of the cutaneous surface, a diffusion over the entirety thereof and at the level of the sebaceous glands. The active ingredients, primarily including a complex of essential oils and of polyunsaturated fatty acids, stored in these sebaceous glands can be salted out progressively with the sebum product to the surface of the skin.Type: ApplicationFiled: February 11, 2011Publication date: August 11, 2011Applicant: LABORATOIRE DE DERMO-COSMETIQUE ANIMALE (L.D.C.A) SASInventor: Lionel FABRIES
-
Publication number: 20110182988Abstract: This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract.Type: ApplicationFiled: June 3, 2009Publication date: July 28, 2011Inventors: Viness Pillay, Yahya Choonara, Caragh Murphy, Sarashnee Moonisami
-
Publication number: 20110152335Abstract: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant.Type: ApplicationFiled: February 25, 2011Publication date: June 23, 2011Applicant: Alwyn Company, Inc.Inventor: Elliott FARBER
-
Publication number: 20110086761Abstract: The present invention relates to fungicidal compositions and their use for controlling oomycete pathogen induced disease or diseases in one or more plants.Type: ApplicationFiled: October 13, 2010Publication date: April 14, 2011Applicant: DOW AGROSCIENCES LLCInventors: Norman R. Pearson, Lei Liu, Robert J. Ehr, John M. Atkinson
-
USE OF POLYMERIC GUANIDINE DERIVATIVES FOR THE CONTROL OF UNWANTED MICROORGANISMS IN CROP PROTECTION
Publication number: 20110003689Abstract: The present invention relates to the use of polymeric guanidine derivatives for the curative and/or preventive treatment of unwanted microorganisms such as bacteria and phytopathogenic fungi in crop protection including the treatment of seed. The invention furthermore relates to novel active compound combinations comprising at least one polymeric guanidine derivative and at least one further fungicidally active compound, their use for the curative or preventive treatment of unwanted microorganisms in crop protection including the treatment of seed and not least the treated seed itself.Type: ApplicationFiled: December 6, 2008Publication date: January 6, 2011Applicant: AKA TECHNOLOGY GMBHInventors: Hans-Juergen Rosslenbroich, Arnd Voerste, Martin Schoepfer, Hilmar Wolf, Ulrike Wachendorff-Neumann, Peter Dahmen, Dirk Ebbinghaus, Oskar Schmidt -
Publication number: 20100333237Abstract: The present invention relates to regulation of ureide levels for optimal plant survival during nutrient remobilization such as occurs during normal growth, dark stress and senescence. Plants can be genetically engineered or selected using a suitable gene marker to have enhanced ureide accumulation. The present invention further provides methods of protecting plants, or extending the shelf life of fresh plant produce by application of exogenous ureides.Type: ApplicationFiled: February 1, 2009Publication date: December 30, 2010Inventors: Robert Fluhr, Moshe Sagi
-
Publication number: 20100317705Abstract: The invention relates to (among other things) oligomer-dantrolene conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.Type: ApplicationFiled: November 14, 2008Publication date: December 16, 2010Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Wen Zhang
-
Patent number: 7795239Abstract: Saccharide compositions and methods of their use to (a) treat functional bowel disorders, (b) gastroesophageal reflux disease and (c) syndromes of nausea, vomiting and diarrhea in man and animals. Also disclosed are saccharide compositions and methods of their use to accelerate the healing of erosions and ulcerated wounds. These same saccharide compositions allow for co-administration and unimpeded uptake of medications traditionally self-adsorbed to saccharides.Type: GrantFiled: December 15, 2004Date of Patent: September 14, 2010Assignee: Mueller Medical International LLCInventor: Ricky W McCullough
-
Publication number: 20100226872Abstract: The present invention is a directed to a composition and method of solubilizing and stabilizing a liquid preservative composition containing an alkyl paraben ingredient which comprises including polyvinyl pyrrolidone (PVP) in said composition. The compositions are particularly useful in personal care products.Type: ApplicationFiled: August 8, 2007Publication date: September 9, 2010Inventors: John J. Merianos, Susan M. Lindstrom, Paul Garelick
-
Publication number: 20100210665Abstract: The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.Type: ApplicationFiled: February 18, 2010Publication date: August 19, 2010Applicant: The Regents of the University of CaliforniaInventors: Charles L. Sawyers, Michael E. Jung, Charlie D. Chen, Samedy Ouk, Derek Welsbie, Chris Tran, John Wongvipat
-
Patent number: 7772230Abstract: The present invention provides a chroman compound of formula (I) and its pharmaceutical salt, methods of its preparation and its pharmaceutical applications. Wherein: X is O or S; n is for 2, 3 or 4; R1 is 6-substituted or 7-substituted halogen, C1-4alkyl, C1-4alkoxyl, benzyloxy, carbamoyl; R2 is nitrogen-containing five-membered or six-membered substituted heterocyclic ring selected from piperidinyl, morpholinyl, N-methyl-piperazinyl, N-(2-ethoxyl)piperazinyl, pyrrolyl, pyrazolyl or imidazolyl. The compounds are useful to prepare medicaments for treating cardiovascular diseases, their preparation employs mild reaction conditions, the raw material are plenty and easy to be obtained, and the operation and post-treatment in the preparation are simple.Type: GrantFiled: October 25, 2007Date of Patent: August 10, 2010Assignee: China Pharmaceutical UniversityInventors: Qidong You, Lvpei Du, Minyong Li, Lin Xia
-
Publication number: 20100183741Abstract: Dermatological compositions contain, formulated into a physiologically acceptable medium, at least one retinoid compound selected from among all-trans retinoic acid, isotretinoin, motretinide, and naphthoic acid compounds of formula (I), and salts and esters thereof: wherein R is a hydrogen atom, a hydroxyl radical, a branched or unbranched alkyl radical having from 1 to 4 carbon atoms, an alkoxy radical having from 1 to 10 carbon atoms or a cycloaliphatic radical which is substituted or unsubstituted, and at least one anti-irritant compound and benzoyl peroxide.Type: ApplicationFiled: December 11, 2009Publication date: July 22, 2010Applicant: GALDERMA RESEARCH & DEVELOPMENTInventor: Claire MALLARD
-
Patent number: 7666859Abstract: Skin compositions comprising, hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and related method for protecting, healing and/or soothing the skin comprising: applying an effective amount of a cosmetic preparation selected from the group consisting of hand cream, foot cream, body cream, lip cream, lip gloss, lip stick, gel, balm and lotion to the skin surface; wherein said cosmetic preparation includes a skin composition made of hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and said effective amount is enough to protect, heal and/or soothe the skin surface.Type: GrantFiled: September 6, 2007Date of Patent: February 23, 2010Inventor: Norman Turkowitz
-
Publication number: 20090306163Abstract: The described invention relates to the formulation and delivery of topical compositions comprising a cosmetically effective amount of at least one imidazolidinedione analog reduce the appearance of wrinkles.Type: ApplicationFiled: June 10, 2009Publication date: December 10, 2009Inventor: Pamela Renee Lipkin
-
Publication number: 20090215730Abstract: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes.Type: ApplicationFiled: May 5, 2006Publication date: August 27, 2009Inventors: Rolando Eduardo Rodriguez Fernandez, Roberto Vera Alvarez, Ania De La Nuez Veulens, Yuliet Mazola Reyes, Silvio Ernesto Perea Rodriguez, Boris Ernesto Acevedo Castro, Alexis Musacchio Lasa, Raimundo Ubieta Gomez